Alvin Cacho
Cardiovascular Disease · Stockton, CANPI 1205918497
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.7% of the total across 626 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,278 and has fallen 65.5% since, to $1,132 in 2025.
Across 626 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novartis$1K
- Boehringer Ingelheim$1K
- Johnson & Johnson$1K
- Boston Scientific$998
- Amgen$742
- plus $7K from 37 others
What the payments were for
- Travel & lodging$5604%
- Food & beverage$12,17191%
- Education$5554%
- Other$1281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,414 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 230 | $202,573 |
| XareltoRivaroxaban | 152 | $143,970 |
| JardianceEmpagliflozin | 87 | $82,913 |
| EntrestoSacubitril/Valsartan | 35 | $35,885 |
| FarxigaDapagliflozin Propanediol | 30 | $33,845 |
| TradjentaLinagliptin | 30 | $25,345 |
| Repatha SureclickEvolocumab | 45 | $24,395 |
| OzempicSemaglutide | 24 | $20,305 |
| VascepaIcosapent Ethyl | 33 | $16,579 |
| MultaqDronedarone Hcl | 17 | $16,132 |
| Ranolazine ErRanolazine | 117 | $15,278 |
| TrulicityDulaglutide | 12 | $11,526 |
| BrilintaTicagrelor | 23 | $10,823 |
| NexlizetBempedoic Acid/Ezetimibe | 14 | $8,207 |
| Metoprolol Succinate | 502 | $7,121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $571 | $202,573230 claims |
| Johnson & JohnsonXarelto | $1,124 | $143,970152 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,153 | $108,258117 claims |
| AstraZenecaFarxiga, Brilinta | $1,440 | $44,66853 claims |
| NovartisEntresto | $1,225 | $35,88535 claims |
| Novo NordiskOzempic | $283 | $20,30524 claims |
| Sanofi-aventis U.S. LLCMultaq | $256 | $16,13217 claims |
| Lilly USA, LLCTrulicity | $109 | $11,52612 claims |
| Esperion Therapeutics, Inc.Nexlizet | $392 | $8,20714 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $69 | $2,51711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Stockton
- Daren PrimackStockton$234K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.